After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Earlier, Yahoo Finance discussed this stock as it revealed Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. The current market capitalization of Avidity Biosciences Inc is $1.91B. A total of 1.92 million shares were traded on the day, compared to an average of 1.18M shares.
In the most recent transaction, MacLean Michael F sold 40,000 shares of RNA for 24.52 per share on Mar 13 ’24. After the transaction, the Chief Financial Officer now owns 44,093 company shares. In a previous transaction on Mar 12 ’24, Boyce Sarah sold 28,000 shares at 22.63 per share. RNA shares that President and CEO owns now total 112,117.
Among the insiders who sold shares, LEVIN ARTHUR A disposed of 27,641 shares on Mar 12 ’24 at a per-share price of $22.03. This resulted in the Director holding 14,830 shares of RNA after the transaction. In another insider transaction, Boyce Sarah sold 84,000 shares at $21.39 per share on Mar 08 ’24. Company shares held by the President and CEO now total 112,117.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. In terms of 52-week highs and lows, RNA has a high of $26.24 and a low of $4.82.
As of this writing, RNA has an earnings estimate of -$0.78 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.67 per share and a lower estimate of -$0.95. The company reported an EPS of -$0.71 in the last quarter, which was 7.80% higher than expectations of -$0.77.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. RNA’s latest balance sheet shows that the firm has $405.54M in Cash & Short Term Investments as of fiscal 2021. There were $11.73M in debt and $29.66M in liabilities at the time. Its Book Value Per Share was $6.32, while its Total Shareholder’s Equity was $381.43M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RNA is Buy with a score of 4.86.
